{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:39:40Z","timestamp":1775086780615,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In Mexico, the incidence of acute myeloid leukemia (AML) has increased in the last few years. Mortality is higher than in developed countries, even though the same chemotherapy protocols are used. CCAAT Enhancer Binding Protein Alpha (<jats:italic>CEBPA<\/jats:italic>) mutations are recurrent in AML, influence prognosis, and help to define treatment strategies. <jats:italic>CEBPA<\/jats:italic> mutational profiles and their clinical implications have not been evaluated in Mexican pediatric AML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the Study<\/jats:title><jats:p>To identify the mutational landscape of the <jats:italic>CEBPA<\/jats:italic> gene in pediatric patients with <jats:italic>de novo<\/jats:italic> AML and assess its influence on clinical features and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>DNA was extracted from bone marrow aspirates at diagnosis. Targeted massive parallel sequencing of <jats:italic>CEBPA<\/jats:italic> was performed in 80 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>CEBPA<\/jats:italic> was mutated in 12.5% (10\/80) of patients. Frameshifts at the N-terminal region were the most common mutations 57.14% (8\/14). <jats:italic>CEBPA<\/jats:italic> biallelic (<jats:italic>CEBPA<\/jats:italic><jats:sup>BI<\/jats:sup>) mutations were identified in five patients. M2 subtype was the most common in <jats:italic>CEBPA<\/jats:italic> positive patients (<jats:italic>CEBPA<\/jats:italic><jats:sup>POS<\/jats:sup>) (<jats:italic>p<\/jats:italic> = 0.009); 50% of the <jats:italic>CEBPA<\/jats:italic><jats:sup>POS<\/jats:sup> patients had a WBC count &amp;gt; 100,000 at diagnosis (<jats:italic>p<\/jats:italic> = 0.004). OS &amp;gt; 1 year was significantly better in <jats:italic>CEBPA<\/jats:italic> negative (<jats:italic>CEBPA<\/jats:italic><jats:sup>NEG<\/jats:sup>) patients (<jats:italic>p<\/jats:italic> = 0.0001). <jats:italic>CEBPA<\/jats:italic><jats:sup>POS<\/jats:sup> patients (either bi- or monoallelic) had a significantly lower OS (<jats:italic>p<\/jats:italic> = 0.002). Concurrent mutations in <jats:italic>FLT3<\/jats:italic>, <jats:italic>CSF3R<\/jats:italic>, and <jats:italic>WT1<\/jats:italic> genes were found in <jats:italic>CEBPA<\/jats:italic><jats:sup>POS<\/jats:sup> individuals. Their contribution to poor OS cannot be ruled out.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CEBPA mutational profiles in Mexican pediatric AML patients and their clinical implications were evaluated for the first time. The frequency of <jats:italic>CEBPA<\/jats:italic><jats:sup>POS<\/jats:sup> was in the range reported for pediatric AML (4.5\u201315%). <jats:italic>CEBPA<\/jats:italic> mutations showed a negative impact on OS as opposed to the results of other studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.899742","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T04:59:19Z","timestamp":1657515559000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Mutational Landscape of CEBPA in Mexican Pediatric Acute Myeloid Leukemia Patients: Prognostic Implications"],"prefix":"10.3389","volume":"10","author":[{"given":"Carolina","family":"Molina Garay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Carrillo S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Leonardo","family":"Flores Lagunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Jim\u00e9nez Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anallely","family":"Mu\u00f1oz Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatr\u00edz Eugenia","family":"Villegas Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilario","family":"Flores Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"N\u00fa\u00f1ez Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elva","family":"Jim\u00e9nez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilma Carolina","family":"Bekker M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Refugio","family":"Torres Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Flores Lujano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Alfonso","family":"Mart\u00edn Trejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minerva","family":"Mata Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Medina Sans\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Eugenia","family":"Espinoza Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Gabriel","family":"Pe\u00f1aloza Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Martha","family":"Espinosa Elizondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz Victoria","family":"Flores Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Amador Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"P\u00e9rez Sald\u00edvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar Alejandro","family":"Sep\u00falveda Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayde\u00e9","family":"Rosas Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Jim\u00e9nez Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Galindo Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Mej\u00eda Arangur\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Alaez Verson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","first-page":"323","article-title":"Epidemiolog\u00eda de las leucemias agudas en ni\u00f1os. Parte 1.","volume":"43","author":"Mej\u00eda Arangur\u00e9","year":"2005","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"B3","first-page":"66","article-title":"Epidemiolog\u00eda descriptiva de la leucemia mieloide aguda (LMA) en ni\u00f1os residentes de la Ciudad de M\u00e9xico: reporte del grupo Mexicano interinstitucional para la identificaci\u00f3n de las causas de la leucemia en ni\u00f1os.","volume":"152","author":"Mej\u00eda-Arangur\u00e9","year":"2016","journal-title":"Gac Med Mex"},{"key":"B4","first-page":"91","article-title":"El ni\u00f1o de poblaci\u00f3n abierta con c\u00e1ncer en M\u00e9xico. Consideraciones epidemiol\u00f3gicas.","volume":"60","author":"Rivera-Luna","year":"2015","journal-title":"An Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jped.2020.02.003","article-title":"Epidemiological evaluation and survival of children with acute myeloid leukemia.","volume":"97","author":"Morais","year":"2021","journal-title":"J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/sj.leu.2403920","article-title":"Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.","volume":"19","author":"Creutzig","year":"2005","journal-title":"Leukemia"},{"key":"B7","first-page":"286","article-title":"Principales causas de mortalidad durante la fase de inducci\u00f3n a la remisi\u00f3n en los pacientes pedi\u00e1tricos con leucemia linfobl\u00e1stica aguda.","volume":"55","author":"Aguilar-Hernandez","year":"2017","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B10","year":"2021","journal-title":"NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia Version 1.2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41417-019-0133-7","article-title":"Companion gene mutations and their clinical significance in AML with double mutant CEBPA.","volume":"27","author":"Zhang","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","article-title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.","volume":"28","author":"Green","year":"2010","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.leu.2403608","article-title":"CEBP\u03b1 mutations in childhood acute myeloid leukemia.","volume":"19","author":"Liang","year":"2005","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3324\/haematol.2010.031336","article-title":"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.","volume":"96","author":"Hollink","year":"2011","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1038\/bcj.2014.47","article-title":"Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: A report from the Japanese pediatric leukemia\/lymphoma study group.","volume":"4","author":"Matsuo","year":"2014","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2003-02-0477","article-title":"Transcription activation function of C\/EBP\u03b1 is required for induction of granulocytic differentiation.","volume":"102","author":"Keeshan","year":"2003","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00586","article-title":"Profiling FLT3 mutations in Mexican acute myeloid leukemia pediatric patients: impact on overall survival.","volume":"8","author":"Molina Garay","year":"2020","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J ASA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3026(16)00002-8","article-title":"Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the childhood leukemia international consortium (CLIC).","volume":"3","author":"Marcotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10654-018-0402-z","article-title":"Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the childhood leukemia international consortium.","volume":"33","author":"Petridou","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B22","first-page":"p. 1993","article-title":"CEBPA-associated familial acute myeloid leukemia (AML)","author":"Tawana","year":"2010","journal-title":"GeneReviews<sup>\u00ae<\/sup> [Internet]"},{"key":"B23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.prp.2016.02.004","article-title":"AML multi-gene panel testing: a review and comparison of two gene panels.","volume":"212","author":"Thakral","year":"2016","journal-title":"Pathol Res Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2015-07-657908","article-title":"Getting a handle on hereditary CEBPA mutations.","volume":"126","author":"DiNardo","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States.","volume":"124","author":"Zavala","year":"2021","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.stem.2009.10.008","article-title":"Mutant CEBPA: priming stem cells for myeloid leukemogenesis.","volume":"5","author":"Somervaille","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-\u03b1 (C\/EBP\u03b1), in acute myeloid leukemia.","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2008.02.008","article-title":"Modeling of C\/EBP\u03b1 mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.","volume":"13","author":"Kirstetter","year":"2008","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.immuni.2004.11.006","article-title":"Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C\/EBP\u03b1.","volume":"21","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations.","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity.","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1200\/JCO.2008.16.5563","article-title":"Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.","volume":"26","author":"Pabst","year":"2008","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12297","article-title":"CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis.","volume":"161","author":"Grossmann","year":"2013","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/cncr.31331","article-title":"Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.","volume":"124","author":"DiNardo","year":"2018","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/leu.2013.273","article-title":"The role of different genetic subtypes of CEBPA mutated AML.","volume":"28","author":"Fasan","year":"2014","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00277-015-2540-7","article-title":"Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.","volume":"95","author":"Ahn","year":"2016","journal-title":"Ann Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ijlh.13517","article-title":"Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.","volume":"43","author":"Mendoza","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4149\/BLL_2018_068","article-title":"Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.","volume":"119","author":"Akin","year":"2018","journal-title":"Bratisl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/sj.leu.2404331","article-title":"A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias.","volume":"20","author":"Lin","year":"2006","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The incidence and clinical significance of nucleophosmin mutations in childhood AML.","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood-2005-03-0899","article-title":"Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.","volume":"106","author":"Cazzaniga","year":"2005","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-41","article-title":"The frequency of NPM1 mutations in childhood acute myeloid leukemia.","volume":"3","author":"Braoudaki","year":"2010","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3324\/haematol.2010.038976","article-title":"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2019.12.030","article-title":"T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form.","volume":"523","author":"Price","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood.2019004179","article-title":"Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia.","volume":"135","author":"Tarlock","year":"2020","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-019-03699-7","article-title":"CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.","volume":"98","author":"Su","year":"2019","journal-title":"Ann Hematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1182\/blood-2010-02-268953","article-title":"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the children\u2019s oncology group.","volume":"116","author":"Ho","year":"2010","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1182\/blood-2008-09-177949","article-title":"Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.","volume":"113","author":"Hollink","year":"2009","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1259","article-title":"Prognostic factors in childhood acute myeloid leukemia. Experience from A Developing Country.","volume":"3","author":"Ghafoor","year":"2020","journal-title":"Cancer Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","article-title":"The genomics of acute myeloid leukemia in children.","volume":"39","author":"Conneely","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1182\/blood-2011-05-353185","article-title":"Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.","volume":"118","author":"Staffas","year":"2011","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood-2019-126273","article-title":"Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation.","volume":"134","author":"Tarlock","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.899742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:16:09Z","timestamp":1659003369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.899742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":52,"alternative-id":["10.3389\/fped.2022.899742"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.899742","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"article-number":"899742"}}